G2G Bio Partners with Celltrion for Ultra-High Concentration SC Formulation Technology Collaboration

Debut of New Platform "InnoBioLAMP"
Expansion of DDS Business into Biopharmaceutical Formulations

G2G Bio, which has focused on developing long-acting injectable formulations, is expanding its business scope with a subcutaneous (SC) injection technology that enables ultra-high concentration delivery of antibody drugs. By collaborating with Celltrion to test the applicability of a new platform for antibodies, the company plans to extend its drug delivery system (DDS) business—which has so far centered on long-acting microspheres—into the area of biopharmaceutical formulations.

On July 30, G2G Bio announced that it has signed a memorandum of understanding (MOU) with Celltrion for cooperation on the "ultra-high concentration antibody SC formulation platform technology." The agreement also includes a material transfer agreement (MTA), which involves exchanging research materials to evaluate the possibility of applying the technology.

Through this agreement, G2G Bio unveiled its new antibody formulation platform "InnoBioLAMP" for the first time. This technology is an expansion of its existing long-acting injectable platform, "InnoLAMP," allowing high-concentration antibody drugs to be administered subcutaneously.

Antibody drugs with large dosage requirements are typically administered intravenously (IV). To switch to subcutaneous injection, it is crucial to have high-concentration formulation technologies that enable a large amount of antibody to be delivered in a small volume. Global pharmaceutical companies are also accelerating efforts to convert antibody drugs to SC formulations.

For G2G Bio, which is entering the antibody market for the first time, this collaboration with Celltrion—who possesses a diverse antibody portfolio and experience in global markets—is viewed as an important opportunity. The two companies plan to explore various ways to apply antibodies to the InnoBioLAMP platform and seek avenues for development collaboration.

Heeyong Lee, CEO of G2G Bio, said, "Our platform has the scalability to successfully execute both long-acting microsphere production and ultra-high-concentration antibody manufacturing within the same system. Through our collaboration with Celltrion, we plan to demonstrate global competitiveness and deliver successful outcomes that will lead to joint research and commercialization in the future."

This content was produced with the assistance of AI translation services.